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Because of the native endothelial lining, small-cal-
iber autogenous venous and arterial conduits have
shown a superior patency to any type of synthetic
graft,1,2 but in many instances they are not available
for reconstructive vascular surgery. Early endothelial-
ization of small-caliber synthetic grafts may help to
improve performance.3,4 The main method to pro-
mote early endothelialization has been to seed these
grafts with endothelial cells generated from autoge-
nous vein.5,6 Disadvantages of this technique include
increased trauma and length of the surgical procedure.
Our previous studies have demonstrated that
cells from the circulation can contribute to graft flow
surface endothelialization (“fallout healing”).7-9
Further studies have shown that the cellular source
of fallout healing originates in the bone marrow.10,11
Granulocyte colony-stimulating factor (G-CSF) is
known to mobilize bone marrow progenitor cells
and increase them in the circulation.12,13 On the
basis of these observations, this study was initiated
to test a new and relatively simple approach to
enhance endothelialization of small-caliber grafts,
using systemic administration of G-CSF.
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Objective: The purpose of this study was to determine whether systemic administration
of granulocyte colony-stimulating factor (G-CSF) would promote endothelialization for
small-caliber Dacron vascular grafts.
Methods: We implanted 4-mm preclotted Dacron grafts in both carotids of 12 dogs. For
a fair comparison, all dogs had a comparable platelet aggregation profile with platelet
aggregation scores less than 30. Five dogs served as controls, and the others were given
7-day subcutaneous injections of G-CSF (10 µg/kg per day), starting on the seventh
postoperative day. The effect of G-CSF was evaluated by white blood cell count, which
showed a 3.7-fold (± 2.7-fold) increase at the end of treatment. Grafts were harvested
at 4 weeks. All G-CSF grafts were patent, and one control occluded. Endothelial-like cell
coverage averaged 80.8% on G-CSF grafts, but only 35.6% for control grafts (P <
.0004). With the exclusion of the anastomotic pannus healing factor, the difference in
endothelial-like cell coverage was even greater (68.5% vs 9.8%; P < .0001).
Immunocytochemical staining and electron microscopy studies demonstrated endothe-
lial cells. Light microscopy also showed that there were more microvessels on and in the
G-CSF grafts than in the control grafts. This study suggests that G-CSF can enhance
early endothelialization of small-caliber vascular grafts. Further studies to determine the
proper dosage and timing are needed before clinical application can be recommended. (J
Vasc Surg 2000;32:116-23.)
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MATERIAL AND METHODS
Twelve mongrel dogs of both sexes with an aver-
age weight of 21.4 ± 2.1 kg were used. All dogs had
comparable platelet aggregation profiles, with
platelet aggregation scores less than 30 after treat-
ment with aspirin, to ensure patent specimens with
valid comparisons.14 Care and use of all animals
complied with the Guide for the Care and Use of
Laboratory Animals, Institute of Laboratory Animal
Resources, Commission on Life Sciences, National
Research Council, Washington, DC, National
Academy Press, 1996.
Graft implantation. The dogs were premedicat-
ed with 0.25 mg/kg of acepromazine and 0.01
mg/kg of atropine. General anesthesia was induced
with 5% thiopental sodium (Pentothal) given intra-
venously and maintained in stage 3 anesthesia with a
combination of halothane and a mixture of nitrous
oxide and oxygen in a 2:1 ratio given through a
closed circuit respirator.
A bilateral carotid implant model with 4-mm ×
6-cm knitted Dacron Bionit II grafts (CR Bard,
Billerica, Mass) was used for this study. With the dog
supine, a midline neck incision was made. The left
and right carotids were dissected. Venous blood was
aspirated from the external jugular vein to preclot
the grafts, using a four-step preclot method.15 After
the carotid arteries were clamped, 5-cm segments
were removed bilaterally, and a 6-cm long segment
of the prepared grafts was interpositioned, with 7-0
Prolene sutures. Flow measurements were taken at
the end of the procedure, using a Transonic flow
meter (Model T-208; Transonic System, Inc, Ithaca,
NY). Hemostasis was attained, and the wounds were
closed.
Postoperatively, all dogs were given oral aspirin
in a dose of 325 mg/d. The seven dogs in the study
group were given subcutaneous injections of human
G-CSF (Filgrastin; Amgen, Thousand Oaks, Calif)
in a dose of 10 µg/kg per day from the seventh post-
operative day for 7 consecutive days. The effect was
evaluated by measuring white blood cell counts in
the peripheral circulation before and after treatment.
The remaining five dogs served as the controls.
Specimen evaluation. The dogs were humanely
killed at 4 weeks after induction of deep general
anesthesia. Heparin at 10,000 IU was given, and the
dog exsanguinated through a right femoral artery
cannula. The specimens were removed, gently
flushed with Dulbecco’s phosphate buffered solu-
tion, opened longitudinally, and rinsed. They were
then pinned and photographed. The flow surface
was stained with 0.5% silver nitrate and viewed
under a 65× stereomicroscope to assess the endothe-
lial-like cell coverage (ELCC) score, expressed as the
percentage of the flow surface covered by endothe-
lial-like cells (ELCs), as delineated by the stain. Four
adjacent longitudinal tissue blocks were taken
through the full wall thickness from each of the loca-
tions—the proximal anastomosis, the middle of the
graft (within the central 2-cm area), and the distal
anastomosis—and studied as follows:
1. Resin-embedded sections stained with hema-
toxylin and eosin for general observations.
2. Wax-embedded sections for immunocyto-
chemical studies, including monoclonal mouse 
antihuman factor VIII/von Willebrand factor 
antibody (DAKO, Code No. M-616, 
Carpinteria, Calif) and canine CD34+ polyclon-
al antibody (supplied by the Fred Hutchinson 
Cancer Research Institute, Seattle, Wash) for 
endothelial cells and monoclonal mouse antihu-
man smooth muscle α-actin antibody (DAKO, 
Code No. M-851) for smooth muscle cells 
(SMCs).
3. Scanning electron microscopy.
4. Transmission electron microscopy.
The thickness of the graft flow surface lining was
measured with a micrometer on the histologic slide,
in the proximal, central, and distal anastomotic
areas. Three points (the ends and the center, on each
slide from the proximal, central, and distal anasto-
motic areas of each graft specimen) were measured
from each slide, and an average thickness was then
calculated. The quantitative data were statistically
evaluated with the paired Student t test; significant
difference was defined as P less than .05.
RESULTS
The white blood cell count, as an indication for
the mobilizing effect of treatment in the G-CSF
dogs, rose 3.7-fold ± 2.7-fold at the end of G-CSF
treatment and dropped to the original baseline lev-
els at the time of death. The average flow rate was
248 ± 82 mL/min for the G-CSF grafts and 295 ±
38 mL/min for the control group (no significant
difference).
All 14 G-CSF grafts were patent at the time of
retrieval; one of the 10 control grafts was occluded.
Grossly, the G-CSF grafts showed larger contiguous
clean and glistening surfaces than the controls
(Figure, A, A´). Perigraft healing was comparable
with a moderately strong adherence in both groups.
The degree of flow surface endothelialization was
significantly higher on the G-CSF grafts (80.8% ±
8.5%) than on the control grafts (35.6% ± 11.7%; P
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Comparison of representative areas of G-CSF grafts with control grafts from untreated subjects. A, A´, Gross specimens.
B, B´, Map of ELCC distribution, showing that cellular coverage on the control grafts was largely restricted to the pan-
nus areas. The views for C, C´ through H, H´ are of areas in the centers of the grafts. C, C´, ELCC delineated by AgNO3
staining, C = ×55, C´ = ×30. Views from D, D´: hematoxylin and eosin staining. D = ×55. D´ = ×55. E, E´, CD34 stain-
ing, showing endothelial cells and microvessels. Inset for E shows endothelial cells and microvessels with apparent origin
on the flow surface. E = ×45, E´ = ×45. F, F´, Smooth muscle α-actin staining. Inset for F shows multiple layers of smooth
muscle cells in the neointima. F = ×50, F´ = ×50. G, G´, Scanning electron microscopy. G = ×320; G´ = ×480. H, H´,
Transmission electron microscopy. H = ×1300, H´ = ×2700.
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< .0004) (Table I). The ELCC on the G-CSF grafts
was uniformly distributed, in contrast to the control
grafts, where it was largely restricted to the pannus
areas (Figure, B, B´). Thus, if the ELCC was com-
pared at the central 4-cm areas (excluding the end 1-
cm areas that most likely resulted from pannus heal-
ing), the difference was even more significant (P <
.0001; Table I).
Histologic study demonstrated that the end 0.5-
to 1-cm area of the graft (the pannus zone) was
completely healed, with almost no differences
between the G-CSF and control grafts. There was
no anastomotic intimal hyperplasia causing stenosis
in either group (Table II). Remarkable healing dif-
ferences were found in the central area of the grafts
between the G-CSF and control groups; histologic
comparisons are presented in the Figure, C-H, C´-
H´. Immunocytochemical staining with factor
VIII/von Willebrand factor and CD34 antibody
demonstrated that the ELCs delineated by silver
nitrate staining had the nature of endothelial cells
(Figure, C-E, C´-E´). An extensive layer of neointima
consisting of several layers of SMCs underneath the
surface endothelial cells was found on the G-CSF
grafts. On a few of the control grafts a sparse neoin-
tima was seen, but most were covered by a layer of
pseudointima with no endothelial cells on the sur-
face. This pseudointima was largely composed of a
fibrin coagulum with some red cells and inflamma-
tory cells (Figure, F, F´). Scanning and transmission
electron microscopy studies showed that on the G-
CSF graft surface there was a contiguous layer of
endothelial cells. Most of the areas on the control
grafts were covered with a film of fibrin-like materi-
al mixed with blood cells (Figure, G-H, G´-H´).
As shown in the Figure, E, microvessels in G-
CSF grafts were remarkably increased, both in terms
of size and numbers, on the surface and in the inti-
ma, as well as the graft wall and adventitia. Many of
them clearly contained blood cells. These were seen
very infrequently in the control grafts (Figure, E´),
and many of them only appeared around the peri-
graft area and outer part of the graft wall.
The comparisons between G-CSF and control
grafts of the flow surface lining thicknesses at the
proximal, middle, and distal areas are presented in
Table II. They were significantly thinner on the G-
CSF grafts than on the control grafts, especially in
the central areas.
DISCUSSION
Since we reported that cells from the circulation
can contribute to graft surface endothelialization,
efforts have been made to determine the mechanism
and cellular source and to find methods to promote
this phenomenon. Studies have shown that mature
endothelial cells are present in the blood flow.16,17
Thus, it is possible that some detachment of the
endothelial lining elsewhere in the cardiovascular
tree could provide the cellular source for fallout.
However, our studies, with the use of a genetic trac-
ing approach, have demonstrated that the main cel-
lular source for fallout is derived from bone marrow,
rather than simple relocation.10,11 Further studies
have supported the concept that the progenitor cells
in bone marrow do have great potential to enhance
graft endothelialization. Fujita et al18 showed that
bone marrow seeded/preclotted Dacron grafts
yielded 80% endothelialization at 1 week. It has been
demonstrated in vitro that CD34+/Flk-1+ cells
under proper conditions can differentiate into
endothelial cells.11 Early and enhanced endothelial-
ization has also been achieved on grafts seeded with
CD34+ cells isolated from bone marrow.19 This
study was part of our continuing effort to increase
the quantity of spontaneous fallout healing.
Table II. Comparison of the thickness (µm) of flow surface lining between the G-CSF and control grafts
Proximal Middle Distal
G-CSF grafts 274.3 ± 86.0 64.3 ± 17.0 311.4 ± 85.1
Control grafts 360.0 ± 56.6 177.6 ± 80.6 387.8 ± 58.7
P value .0218 .0001 .0356
Table I. ELCC scores for grafts from dogs treated with G-CSF, compared with grafts from untreated dogs
ELCC (%) ELCC (%)
G-CSF grafts (n = 14) Control grafts (n = 9) P value
Total surface 80.8 ± 8.5 35.6 ± 11.7 < .0004
Central 4 cm 68.5 ± 8.1 9.8 ± 4.2 < .0001
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Hematopoiesis requires cytokines collectively
termed colony-stimulating factors, such as G-CSF,
macrophage colony-stimulating factor, and granulo-
cyte-macrophage colony-stimulating factor. They
are glycoproteins that act on progenitor cell popula-
tions and direct them to a specific lineage.12
Clinically, G-CSF is commonly used to mobilize the
progenitors of neutrophils.12,13
In this study, G-CSF may have played multiple
roles in the enhancement of graft endothelialization.
Studies have shown that G-CSF can stimulate and
promote the growth, differentiation, and activation
of progenitor cells. With the administration of G-
CSF, the number of circulating progenitor cells in
the treated dogs was increased, as indicated by a 3.7-
fold increase of the white blood cell count at the end
of treatment. Recent studies have demonstrated that
endothelial cells can be derived from CD34+/Flk-1+
cells, suggesting that endothelial and hematopoietic
cells originate from common precursors.11,20-22
Thus, the increased circulating progenitor cells gen-
erated by G-CSF may have included a subpopulation
of endothelial progenitor cells, such as CD34+/Flk-
1+ cells, and provided a substantially greater source
for fallout healing. This may explain the significant-
ly higher degree of endothelialization on G-CSF
grafts than on control grafts (Table I). In addition,
Bussolino et al have shown that G-CSF can induce
the migration and proliferation of vascular endothe-
lial cells.23-26
We found that in G-CSF–treated grafts, microves-
sel formation was enhanced on the flow surface, in the
wall, and in the perigraft areas. Those microvessels
were lined with endothelial cells (Figure, E). We had
earlier observed a similar phenomenon in grafts seed-
ed with either bone marrow or CD34+ cells.18,19
Because studies have demonstrated that progenitor
cells can differentiate into endothelial cells,11
microvessel formation is possibly one of the manifes-
tations during this process. Asahara et al’s20 report
supports this assumption: they found that CD34+/
Flk-1+ cells formed microvessels in a rabbit hind limb
ischemic model.22 Clowes et al27 have demonstrated
the role of transmural microvessel ingrowth in graft
surface endothelialization. The enhanced surface
endothelialization of the treated grafts may also be
associated with increased microvessel formation. In
addition, Kojima et al28 reported the release of plas-
minogen activation by aortic endothelial cells stimu-
lated by G-CSF. Janowaska-Wieczorek et al29 recent-
ly reported that growth factors and cytokines upregu-
late matrix metalloproteinase expression in bone
marrow CD34+ cells and their transmigration. This
proteolytic activity may facilitate the sprouting of
endothelial cells and microvessels.
An organized thin layer of SMCs underneath the
surface endothelial lining was found on the G-CSF
grafts (Figure, F). Porous knitted Dacron grafts were
used in this study. These SMCs were very possibly
associated with transmural tissue ingrowth from peri-
graft tissue.27 However, in our previous fallout heal-
ing studies, where only the cells in the circulating
blood could reach the impervious study graft’s flow
surface with exclusion of any other cell sources, we
repeatedly found SMCs on the surface lining.7-9 Our
studies also showed that the main cellular source for
fallout was bone marrow.10,11 Thus, the other two
possible origins for the SMCs could be suggested.
One possibility is that bone marrow might contain
SMC precursors as well as endothelial cell precursors,
which were also mobilized after the G-CSF treatment.
Galmiche et al30 found that stromal cells of bone mar-
row were similar to vascular SMCs with regard to
their composition and actin isoform expression. The
other possibility is that the endothelial cells derived
from bone marrow progenitors may further transform
or transdifferentiate into SMCs. This assumption was
supported by the reports of Williams et al31,32 and
Drake et al.33 The SMC proliferation and intimal
hyperplasia are always a concern, especially in small-
caliber grafts. Many studies have shown that endothe-
lial cells markedly inhibit SMC proliferation and their
collagen synthesis and have suggested that absence of
normal endothelial cell function would contribute to
intimal hyperplasia.34-38 In this study, a significantly
thinner graft surface lining was found on the G-CSF
grafts than on the control grafts (Table II). This may
be associated with the more complete endothelializa-
tion on their surface, as suggested by the studies cited
above (Table I). Of course, further proof needs to be
supported by long-term studies.
Graft healing and progenitor differentiation are
dynamic processes. Although this experimental study
showed an enhancing effect of G-CSF on graft
endothelialization, a critical issue (the proper time to
start the administration of G-CSF and the length of
treatment) was not studied. Because canine G-CSF is
not commercially available, we used human G-CSF in
this study. To prevent heterogeneous protein-related
immunologic side effects, we had to limit the duration
of G-CSF administration and implant time.39 When
canine G-CSF becomes available, there will be more
flexibility to test various treatment regimens for opti-
mal results and to study patency rates with a longer
implant time to further evaluate the results of G-CSF
treatment. The dose we used was based on other stud-
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ies.12 White blood cell counts in this study increased
only about 3.7-fold; other studies have reported
greater mobilization.12,40 This may be associated with
the use of cross-species G-CSF. Presumably, the high-
er the level of progenitor cell mobilization, the greater
the enhancement of graft endothelialization. We start-
ed G-CSF treatment a week after graft implantation,
according to the assumption that by that time, the
graft surface would be covered with a layer of fibrinous
material that could serve as a matrix to facilitate pro-
genitor cell adherence and growth.22,41,42 For the
same purpose, combining the G-CSF treatment with
other factors that can facilitate and promote progeni-
tor cell adherence and growth may further enhance
the G-CSF effect.
This study showed that G-CSF could enhance
graft surface endothelialization. Systemic adminis-
tration of G-CSF can be easily adapted to clinical
application, because it is known to have few side
effects. If an optimal schedule for administration can
be determined, it has the potential to become a use-
ful clinical approach for the enhancement of early
small-caliber graft endothelialization.
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DISCUSSION
Dr Julie Ann Freischlag (Los Angeles, Calif). This is a
very fine basic science paper that explores the use of
human G-CSF (granulocyte colony-stimulating factor),
which is known to mobilize bone marrow progenitor cells
into the systemic circulation, in a dog model of carotid
artery Dacron interposition grafts. The G-CSF was given
subcutaneously from postoperative day 7 to 14. Four
weeks later the grafts in the experimental group receiving
G-CSF demonstrated elevated white blood cell counts,
larger areas of surface endothelialization than controls
(80.8% ± 8.5% versus 35.6% ± 11.7%) with uniform distri-
bution of the cells, and an extensive layer of neointima
consisting of smooth muscle cells. Microvessels in the G-
CSF grafts were also increased in size and number con-
taining blood cells. I have five questions:
1. Since you used human G-CSF in a dog model, what
effects did you see that may be related to this species
difference and not to just G-CSF alone?
2. Have you observed a different graft, such as PTFE or
coated Dacron or a vein graft, with the administration
of G-CSF?
3. Why did you give the dogs aspirin postoperatively?
4. What are any potential side effects of using G-CSF?
5. Can you more specifically explain how G-CSF stimu-
lates the formation of microvessels into the graft?
I enjoyed reading the paper and discussing this fine
piece of work. Thank you.
Dr Moses Wu. Dr Freischlag: Thank you. Your first ques-
tion concerned the cross-species–related G-CSF effect.
Presently, only human G-CSF is commercially available,
and canine G-CSF is exclusively available only for contract
research with the manufacturer (the Amgen Co). The
mobilizing effect of human G-CSF on dogs was observed
in our study and others. However, Hammond et al have
reported that the heterogenous protein-related immuno-
logical side effect, neutropenia, was observed in dogs
between 3 and 4 weeks after receiving human G-CSF
treatment. In order to prevent this, we had to limit our
study time period to 4 weeks, before this side effect could
occur. As we mention in our manuscript, when canine G-
CSF becomes available, a more flexible regimen can be
studied. The research groups at Fred Hutchinson Cancer
Research Center (Seattle) use canine G-CSF on dogs for
progenitor cell mobilization before marrow transplantation.
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They informed me that they have not observed any major
side effects when using canine G-CSF on dogs. Another
research group in Japan reported that human G-CSF could
have a mobilization effect on rabbits, but that it may induce
leukocytosis. Our study dogs developed neither neutrope-
nia nor leukocytosis, and their WBCs returned to normal
baselines at the end of the study.
In answer to your second question, “Did we do any
study using PTFE, coated Dacron, or autogenous veins
associated with G-CSF treatment?” no, we did not. But
we did observe similar enhancement of endothelialization
in impervious Dacron grafts that had been modified by
our laboratory to study fallout healing.
Your third question regarded the purpose of using
aspirin on the dogs. In our study, small-caliber (4 mm)
grafts were used. Experimentally, most of the occlusion in
small-caliber grafts occurred between 3 and 4 weeks. We
did not expect that G-CSF could protect early patency of
small-caliber grafts before enhanced flow surface endothe-
lialization was achieved. We also know that platelet aggre-
gability varies among dogs, and it plays an important role
in graft patency. We did measure the platelet aggregation
score before and after aspirin treatment. In order to have
a valid, patent graft for study and a fair comparison
between study and control groups, we only used dogs
with platelet aggregation scores of less than 30 after
aspirin treatment for both the study and control groups.
Concerning your fourth question, clinically, there
have been no reports of major side effects with the use of
G-CSF. The most common minor side effect has been
pain in the bones and the joints. G-CSF may also increase
inflammation, such as worsening existing arthritis. There
was one case report from Japan that acute arterial throm-
bosis occurred because of increased platelet count and
aggregation with G-CSF treatment.
Your fifth and last question regards the mechanisms of
increased microvessel formation, an especially important
topic. Increased microvessel formation was observed as a
phenomenon in our study, but we could not provide data
to explain the mechanism. In bone marrow, hematopoiet-
ic progenitor cells include the hemangioblasts. Recent
studies have demonstrated that hematopoietic cells can
differentiate into endothelial cells. Presumably, as a result
of the G-CSF mobilization effect, the hemangioblasts and
the progenitor cells both had all increased in the blood cir-
culation. This possibly was the main mechanism for
increased microvessel formation in our study.
Dr Freischlag, again, I thank you for your valuable
comments.
Dr Glenn Hunter (Galveston, Tex). Dr Wu, I enjoyed
your paper. Have you followed any grafts long term? One
of the things that intrigues me, is whether giving a dog
granulocyte-stimulating factor for a short period of say 2
or 4 weeks and then stopping, influences the thickness of
the neointima? Do the smooth muscle cells continue to
proliferate, or do they become senescent?
Dr Wu. We did not study grafts implanted longer than
4 weeks. The use of human G-CSF limited our ability to
study grafts with different implantation schedules. When
the canine G-CSF become available, we will plan to do so. 
Dr Hunter. The other question I was going to ask is
whether you think dendritic cells, one of the progenitor
cells that may be present when you administer GSF, dif-
ferentiate into macrophages and induce growth factors
such as vascular endothelial growth factor, which could
potentially explain the increase in microvessel ingrowth.
Dr Wu. Yes, it may be true. In our manuscript, we
briefly discussed possible contributions from the growth
factors.
